Press release
Next Astellas Site will Implement Werum’s PAS-X
Astellas’ Production Site in Kerry, Ireland
One of the leading Japanese pharma groups chooses Werum again
Lueneburg, Germany, 24 April 2012 – Astellas Ireland Co. Ltd. (Kerry Plant) has decided to implement Werum´s PAS-X MES at its production facility in Killorglin, County Kerry, Ireland. The MES will introduce efficient and state-of-the-art paperless Electronic Batch Recording functionality supporting compliant, efficient and lean production processes. The MES will be fully integrated with the SAP ERP system, the shop floor equipment and process control systems. Astellas intends to roll out the MES to all production processes in a phased approach.
Astellas is the second largest pharmaceutical group in Japan with three European production sites. Werum’s PAS-X is already installed in the Astellas site in Meppel, the Netherlands.
About Werum Software & Systems AG
With over 40 years of software development experience, Werum Software & Systems AG is known worldwide for partnering with its global customers to create state-of-the-art software products and solutions. Internationally networked teams of top experts develop software solutions for corporate groups known the world over. Werum is the internationally leading supplier of Manufacturing Execution Systems (MES) for the pharmaceutical and biopharmaceutical industries. Its successful and well-established Manufacturing IT Business Platform PAS-X is used by 16 of the world’s top 30 pharmaceutical and biotech companies in more than 600 installations. Founded in 1969, the IT company employs about 450 people at its headquarters in Lueneburg, Germany, and at eight other locations in Germany, France, the United States, Japan, and Singapore. For more information take a look at our websites at www.werum.com and www.pas-x.com.
Dirk Ebbecke
Director Corporate Communications
Werum Software & Systems AG
Wulf-Werum-Strasse 3
21337 Lueneburg, Germany
Tel. +49 4131 8900-689
Fax +49 4131 8900-20
dirk.ebbecke@werum.com
For further information, visit Werum’s press center at www.press.werum.com.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Next Astellas Site will Implement Werum’s PAS-X here
News-ID: 218950 • Views: …
More Releases from Werum Software & Systems AG
Research Made Easy
With their web-based data management system DSHIP the German-based company Werum Software & Systems supports maritime research on board of research vessels all over the world.
The Instagram profile of the current climate research expedition MOSAiC in the North Polar Sea shows straightaway: research work on the high seas may be really fascinating, but it also is extremely laborious, fragmented and highly complex. As they depend on the various environmental conditions…
Werum’s "PAS-X Reports & Labels" Content Packages significantly reduce MES imp …
Werum’s "PAS-X Reports & Labels" Content Packages significantly reduce MES implementation times
Best practice consulting services and “Out of the Box”-templates for GMP-compliant reports and labels
Lueneburg, Germany, 29 January 2014 – By providing "PAS-X Reports & Labels" Content Packages, Werum Software & Systems now offers an even broader range of pre-configured reports and labels along with the associated comprehensive consulting services to its customers.
These packages are based on best practices…
Werum accelerates MBR creation by providing "PAS-X MBR Design Elements" Content …
Werum accelerates MBR creation by providing "PAS-X MBR Design Elements" Content Packages
New "PAS-X MBR Design Elements" Content Packages based on industry best practice / process-specific and fast MBR creation for pharmaceutical production
Lueneburg, Germany, 28 November 2013 – In order for pharma and biotech customers to implement PAS-X MES projects even faster and more easily, Werum Software & Systems expands its PAS-X Content Packages offering further: New on the market are…
Werum equips research vessel Mya II of Alfred Wegener Institute with DSHIP softw …
Werum equips research vessel Mya II of Alfred Wegener Institute with DSHIP software
AWI puts new RV Mya II into service / Werum's data management system DSHIP ensures acquisition, archiving and evaluation of measurement data
Lueneburg, Germany, 23 October 2013 – The new RV Mya II, which has only recently been delivered to the German Alfred Wegener Institute, Helmholtz Center for Polar and Marine Research (AWI), has been equipped by Werum Software…
More Releases for Astellas
OAB Treatment Market 2020 Productivity Data Analysis by Key Company's (Astellas …
Global OAB Treatment Market: Overview
The overactive bladder treatment market includes various therapies, namely, anticholinergics, mirabegron, BOTOX, and neurostimulation used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall leading to urinary urgency, frequency, nocturia, and urge-incontinence
Get Access to Report Sample @ https://www.businessindustryreports.com/sample-request/240473
Global OAB Treatment Market: Growth Factors
The growth of market is majorly driven by the increasing geriatric population and consequently rising prevalence of bladder overactivity,…
What's driving the Diabetic Neuropathy Market Growth? Prominent Players: Pfizer, …
The Global Diabetic Neuropathy Market to gain from rapid technological advancements taking place in the market. Recently Fortune Business Insights has published a report, titled Diabetic Neuropathy Market Size, Share And Global Trend By Type (Peripheral, Proximal, Autonomic, Focal), By Drug Class (Non-steroidal Anti-inflammatory Drugs, Antisiezure Drugs, Opioid Drugs, Anti-depressants), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And Geography Forecast Till 2026.
Browse Full Report@ https://www.fortunebusinessinsights.com/industry-reports/diabetic-neuropathy-market-100598
Top Key Players Covered:
Company…
Primary Immunodeficiency Diseases Treatment Market | Astellas, AstraZeneca, Baxt …
HTF MI comprehensive and detailed 101-page research study on Global Primary Immunodeficiency Diseases Treatment provides a significantly expanded scope with deeply analyzed conclusions and content that includes an industry relevant database of major existing Primary Immunodeficiency Diseases Treatment manufacturers/players in each region, analysis of 11 leading national markets, important regions [United States, EU, Japan, China, India & Southeast Asia], a description of major geopolitical trends, analysis of the influencing factors…
Pertussis Vaccine Market Report for Period 2011 till 2023 Mitsubishi Tanabe Phar …
Global Pertussis Vaccine market report provides detailed analysis of companies namely Life Sciences, Beijing Tiantan, Biological Products, Chengdu Institute of, Biological Products, Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, Astellas Pharma, Minhai Biotechnology, Wuhan Institute of, Biological Products, Changchun Changsheng and Others. This report study includes global market statistics and analysis for example, company performance, historical analysis 2012 to 2016, market forecast 2017 to 2023 in terms of volume, revenue, YOY…
Tacrolimus Market 2017- Astellas, Novartis, Hisun
Marketreports.biz, recently published a detailed market research study focused on the "Tacrolimus Market" across the global, regional and country level. The report provides 360° analysis of "Tacrolimus Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Tacrolimus industry, and estimates the future trend of Tacrolimus market on the basis of this…
Astellas Pharma and BioFocus sign target discovery agreement
BioFocus announced today that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders. Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.
“We are delighted to support Astellas Pharma…
